Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy

AIDS

Volumn 16, Issue 7, 2002, Pages 1019-1029

  Dianne Langford, T ^a   Letendre, Scott L ^a   Marcotte, Thomas D ^a   Ellis, Ronald J ^a   McCutchan, J Allen ^a   Grant, Igor ^a   Mallory, Margaret E ^a   Hansen, Lawrence A ^a   Archibald, Sarah ^a   Jernigan, Terry ^a   Masliah, Eliezer ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; HIV leukoencephalopathy

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; DEMENTIA; DEMYELINATING DISEASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LEUKOENCEPHALOPATHY; MALE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; DEMYELINATING DISEASES; DISEASE PROGRESSION; GLIOSIS; HIV-1; HUMANS; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONOCYTES; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; VIRUS REPLICATION;

EID: 0037013041     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200205030-00008     Document Type: Article

References (65)

1. HIV chemotherapy
2. Changing patterns of morbidity and mortality in HIV disease
3. Changes in pathological findings at autopsy in AIDS cases for the last 15 years
4. Neuropathology and general autopsy findings in AIDS during the last 15 years
5. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy
6. Pharmacological frontiers in the treatment of AIDS dementia
7. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998
8. Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy
9. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia
10. HIV-associated disease of the nervous system: Review of nomenclature and proposal for neuropathology-based terminology
11. Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia
12. Human immunodeficiency virus (HIV) leukoencephalopathy and the microcirculation
13. AIDS-related focal brain lesions in the era of highly active antiretroviral therapy
14. Magnetic resonance imaging morphometic analysis of cerebral volume loss in human immunodeficiency virus infection
15. Dendritic injury is a pathological substrate for human immuno-defficiency virus-related cognitive disorders
16. The HNRC 500 - Neuropsychology of HIV infection at different disease stages
17. Neurocognitive impairment is an independent risk factor for death in HIV infection
18. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force
19. Neuropsychological impairment in human immunodeficiency virus-infection: Implications for employment
20. Spectrum of human immunodeficiency virus-associated neocortical damage
21. Distribution of brain HIV load in AIDS
22. Comparison of magnetic resonance imaging with neuropathological findings in the diagnosis of HIV and CMV associated CNS disease in AIDS
23. Synthesis of digoxigenin-labelled DNA probe by polymerase chain reaction: Application to Epstein-Barr virus and Chlamydia trachomatis
24. Herpes simplex virus postmortem multiple sclerosis brain tissue
25. Brain viral burden in HIV infection
26. Shift of prevalence and selected characteristics in hiv-1-related neurologic disorders in HAART Era: Data from the Italian Register Investigative NeuroAIDS (IRINA)
27. Human immunodeficiency virus (HIV) infection in brains with AIDS-related leukoencephalopathy
28. Acute diffuse leukoencephalitis in HIV-1 infection
29. HIV-1 infection of subcortical astrocytes in the pediatric central nervous system
30. Multifocal necrotizing leukoencephalopathy with pontine predilection in immunosuppressed patients: A clinicopathologic review of 16 cases
31. Histopathologic features in the central nervous system of 400 acquired immunodeficiency cases: Implications of rates of occurrence
32. Multiple sclerosis-like illness occurring with human immunodeficiency virus infection
33. Relapsing and remitting human immunodeficiency virus-associated leukoencephalomyelopathy
34. HIV-1 Tat protein stimulates in vivo vascular permeability and lymphomononuclear cell recruitment
35. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia
36. Development of HIV encephalitis in AIDS and TNF-alpha regulatory elements
37. ADEM: Distinct disease or part of the MS spectrum?
38. Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy
39. Measurement of viral sequences in cerebrospinal fluid of AIDS patients with cerebral white-matter lesions using polymerase chain reaction
40. HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS: Effect of neocortical involvement
41. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine
42. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
43. Epidemiology of the human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
44. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy
45. Toxic Leukoencephalopathy
46. Immunorestitution disease involving the innate and adaptive response
47. Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: Evidence for monocyte trafficking into brain
48. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy
49. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients
50. HIV protease inhibitor-related lipodystrophy syndrome
51. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
52. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy
53. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease
54. Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex (ADC): Evidence for neurotropic HIV variants
55. In vivo compartmentalization of human immunodeficiency virus: Evidence for the examination of pol sequences from autopsy tissues
56. Evidence for late stage compartmentalization of HIV-1 resistance mutation between lymph node and peripheral blood mononuclear cells
57. Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy
58. Efficient infection of brain microvascular endothelial cells by an in vivo-selected neuroinvasive SIVmac variant
59. HIV-1 infection of cultured human adult oligodendrocytes
60. Morphological correlates of neurological dysfunction in macaques infected with neurovirulent simian immunodeficiency virus
61. Neuropathogenesis of chimeric simian/human immunodeficiency virus infection in pig-tailed and rhesus macaques
62. Neurobiology of simian and feline immunodeficiency virus infections
63. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
64. Limits to potent antiretroviral therapy
65. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy